Caribou Biosciences shares jump 14.73% intraday after Clear Street initiates Buy rating with $13 target on positive CAR-T trial data.

Caribou Biosciences surged 14.73% intraday following Clear Street’s initiation of coverage with a "Buy" rating and a $13.00 price target, signaling strong upside potential from its $1.45 level. The firm highlighted the company’s promising allogeneic CAR-T pipeline, including 92% and 82% overall response rates in Phase 1 trials for CB-011 and vispa-cel, respectively. These results, coupled with positive safety and cost-efficiency profiles, reinforced investor confidence. Additionally, Leerink Partners and Truist Securities raised price targets to $4.00 and $7.00, respectively, further underscoring the stock’s clinical and commercial potential. The move reflects optimism around Caribou’s ability to deliver durable, scalable gene-editing therapies in a competitive market.